- Home
- CODA vs BDTX Comparison
CODA vs BDTX Comparison
Compare CODA & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CODA | BDTX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.0M | 140.7M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CODA | BDTX |
|---|---|---|
| Price | $13.99 | $2.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 211.5K | ★ 607.1K |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.62 | ★ 32.45 |
| EPS | 0.37 | ★ 0.65 |
| Revenue | ★ $20,316,161.00 | N/A |
| Revenue This Year | $20.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.41 | ★ $3.78 |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $5.76 | $1.20 |
| 52 Week High | $14.89 | $4.94 |
Technical Indicators
Market Signals| Indicator | CODA | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 48.30 |
| Support Level | $6.74 | $2.19 |
| Resistance Level | N/A | $2.86 |
| Average True Range (ATR) | 0.94 | 0.11 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 76.70 | 55.88 |
Price Performance
Historical ComparisonAbout CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.